MLTX
NASDAQMoonLake Immunotherapeutics
News · 26 weeks36+50%
2025-12-072026-05-31
Mix1790d
- SEC Filings6(35%)
- Insider5(29%)
- Other4(24%)
- Analyst2(12%)
Latest news
25 items- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MoonLake ImmunotherapeuticsSCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
- INSIDERChief Financial Officer Bodenstedt Matthias sold $273,333 worth of Class A ordinary shares (13,653 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,172,431 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECSEC Form 10-Q filed by MoonLake Immunotherapeutics10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- PRMoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial ResultsMoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for sonelokimab (SLK) in hidradenitis suppurativa (HS)This included the acceptability of MIRA trial data to establish substantial evidence of effectiveness (SEE), full inclusion of the VELA-TEEN trial data for a label including patients aged 12 years and above, and the strategy for inclusion of safety data across the MIRA and VELA trials – this aligns with the scenario presented at the Investor Day on February 23, 2026The proposed label in HS is therefore expected to include the MIRA
- SECSEC Form DEFA14A filed by MoonLake ImmunotherapeuticsDEFA14A - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECSEC Form DEF 14A filed by MoonLake ImmunotherapeuticsDEF 14A - MoonLake Immunotherapeutics (0001821586) (Filer)
- INSIDERSEC Form 4 filed by Bodenstedt Matthias4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Santos Da Silva Jorge4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Bodenstedt Matthias4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Bvf Partners L P/Il4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by MoonLake ImmunotherapeuticsSCHEDULE 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
- SECSEC Form 144 filed by MoonLake Immunotherapeutics144 - MoonLake Immunotherapeutics (0001821586) (Subject)
- PRMoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingResults from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis of different hallmark lesions of HS shows that up to 25% of patients achieved inflammatory remission at Week 40, defined as a 100% reduction in abscesses (A100), nodules (N100) and draining tunnels (DT100)Patients treated with SLK also showed substantial improvements in HiSQOL items at week 40 versus baseline, ranging from 41% (pain), to 54% (walking, getting dressed) to 62% (down or depressed)Up to
- ANALYSTMoonLake Immunotherapeutics upgraded by Wolfe Research with a new price targetWolfe Research upgraded MoonLake Immunotherapeutics from Underperform to Outperform and set a new price target of $24.00
- ANALYSTMoonLake Immunotherapeutics upgraded by Rothschild & Co Redburn with a new price targetRothschild & Co Redburn upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $40.00
- SECSEC Form 10-K filed by MoonLake Immunotherapeutics10-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECMoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- PRMoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial ResultsIn the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRIaxSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease modifica
- SECSEC Form SCHEDULE 13G filed by MoonLake ImmunotherapeuticsSCHEDULE 13G - MoonLake Immunotherapeutics (0001821586) (Subject)
- PRImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical OfficerBrings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo
- PRMoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor DayThe Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trialThe upcoming Phase 3 program will therefore be expected to benefit from earlier and more frequent interactions with the FDA under the Fast Track program, potentially enabling a more efficient development pathway This regulatory decision follows the recent clear guidance from the FDA, in which the Company confirmed its clinical evidence strategy for the planned submission of a Biologic License Application (BLA) in H2 2026 for SLK in hidradenitis suppurativa (H
- ANALYSTMoonLake Immunotherapeutics downgraded by Goldman with a new price targetGoldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00
- INSIDERSEC Form 4 filed by Chief Scientific Officer Reich Kristian4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
MLTX FAQ
7 questionsWhat does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.Where does MLTX stock trade?
MoonLake Immunotherapeutics (MLTX) is listed on NASDAQ.What sector and industry is MLTX in?
MoonLake Immunotherapeutics operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MoonLake Immunotherapeutics go public?
MoonLake Immunotherapeutics (MLTX) completed its IPO in 2020.What are analysts saying about MLTX?
MoonLake Immunotherapeutics has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $2400.00 price target on 2026-03-23.What companies are similar to MLTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MLTX side-by-side with any of them on Quantisnow.How can I track MLTX on Quantisnow?
Quantisnow aggregates MoonLake Immunotherapeutics's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLTX to receive live email and push alerts on every new disclosure.